|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATAD2B |
Gene summary for ATAD2B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATAD2B | Gene ID | 54454 |
| Gene name | ATPase family AAA domain containing 2B | |
| Gene Alias | ATAD2B | |
| Cytomap | 2p24.1-p23.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9ULI0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54454 | ATAD2B | CCI_1 | Human | Cervix | CC | 1.02e-02 | 8.10e-01 | 0.528 |
| 54454 | ATAD2B | CCI_2 | Human | Cervix | CC | 2.62e-10 | 1.08e+00 | 0.5249 |
| 54454 | ATAD2B | CCI_3 | Human | Cervix | CC | 4.99e-06 | 7.66e-01 | 0.516 |
| 54454 | ATAD2B | HTA11_3410_2000001011 | Human | Colorectum | AD | 5.71e-13 | -5.98e-01 | 0.0155 |
| 54454 | ATAD2B | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.09e-02 | -7.45e-01 | 0.0216 |
| 54454 | ATAD2B | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.97e-05 | -4.11e-01 | -0.1207 |
| 54454 | ATAD2B | HTA11_696_2000001011 | Human | Colorectum | AD | 1.38e-04 | -3.20e-01 | -0.1464 |
| 54454 | ATAD2B | HTA11_866_3004761011 | Human | Colorectum | AD | 1.71e-06 | -5.21e-01 | 0.096 |
| 54454 | ATAD2B | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.92e-02 | -6.10e-01 | 0.0528 |
| 54454 | ATAD2B | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.70e-03 | -5.06e-01 | 0.0338 |
| 54454 | ATAD2B | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.50e-10 | -4.75e-01 | 0.0674 |
| 54454 | ATAD2B | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.82e-02 | -5.16e-01 | 0.0112 |
| 54454 | ATAD2B | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.08e-05 | -6.23e-01 | 0.0588 |
| 54454 | ATAD2B | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.31e-18 | -5.47e-01 | 0.294 |
| 54454 | ATAD2B | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.41e-22 | -5.56e-01 | 0.3859 |
| 54454 | ATAD2B | HTA11_99999973899_84307 | Human | Colorectum | MSS | 8.33e-03 | -6.08e-01 | 0.2585 |
| 54454 | ATAD2B | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.65e-08 | -4.47e-01 | 0.3005 |
| 54454 | ATAD2B | F007 | Human | Colorectum | FAP | 2.68e-03 | -3.68e-01 | 0.1176 |
| 54454 | ATAD2B | A015-C-203 | Human | Colorectum | FAP | 6.05e-30 | -4.03e-01 | -0.1294 |
| 54454 | ATAD2B | A015-C-204 | Human | Colorectum | FAP | 2.66e-05 | -2.61e-01 | -0.0228 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00063257 | Cervix | CC | chromatin organization | 78/2311 | 409/18723 | 5.40e-05 | 8.02e-04 | 78 |
| GO:00063381 | Cervix | CC | chromatin remodeling | 45/2311 | 255/18723 | 8.33e-03 | 4.30e-02 | 45 |
| GO:00063258 | Endometrium | AEH | chromatin organization | 64/2100 | 409/18723 | 3.69e-03 | 2.52e-02 | 64 |
| GO:000632513 | Endometrium | EEC | chromatin organization | 65/2168 | 409/18723 | 4.98e-03 | 3.14e-02 | 65 |
| GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
| GO:00063255 | Liver | NAFLD | chromatin organization | 64/1882 | 409/18723 | 2.31e-04 | 3.89e-03 | 64 |
| GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
| GO:00063256 | Lung | IAC | chromatin organization | 69/2061 | 409/18723 | 2.01e-04 | 3.53e-03 | 69 |
| GO:000632512 | Lung | AIS | chromatin organization | 62/1849 | 409/18723 | 4.24e-04 | 7.29e-03 | 62 |
| GO:000632510 | Oral cavity | OSCC | chromatin organization | 190/7305 | 409/18723 | 1.17e-03 | 5.97e-03 | 190 |
| GO:000632515 | Oral cavity | EOLP | chromatin organization | 84/2218 | 409/18723 | 2.68e-07 | 8.16e-06 | 84 |
| GO:00063383 | Oral cavity | EOLP | chromatin remodeling | 46/2218 | 255/18723 | 2.34e-03 | 1.44e-02 | 46 |
| GO:000632521 | Oral cavity | NEOLP | chromatin organization | 70/2005 | 409/18723 | 4.97e-05 | 6.83e-04 | 70 |
| GO:00063259 | Prostate | BPH | chromatin organization | 101/3107 | 409/18723 | 1.52e-05 | 1.94e-04 | 101 |
| GO:00063382 | Prostate | BPH | chromatin remodeling | 62/3107 | 255/18723 | 9.47e-04 | 5.97e-03 | 62 |
| GO:000632514 | Prostate | Tumor | chromatin organization | 104/3246 | 409/18723 | 2.02e-05 | 2.62e-04 | 104 |
| GO:000633811 | Prostate | Tumor | chromatin remodeling | 63/3246 | 255/18723 | 1.73e-03 | 1.02e-02 | 63 |
| GO:000632520 | Thyroid | PTC | chromatin organization | 183/5968 | 409/18723 | 2.55e-08 | 5.70e-07 | 183 |
| GO:00063385 | Thyroid | PTC | chromatin remodeling | 106/5968 | 255/18723 | 6.56e-04 | 4.13e-03 | 106 |
| GO:0006325110 | Thyroid | ATC | chromatin organization | 189/6293 | 409/18723 | 6.40e-08 | 1.13e-06 | 189 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATAD2B | SNV | Missense_Mutation | c.3967N>A | p.Glu1323Lys | p.E1323K | Q9ULI0 | protein_coding | tolerated(0.4) | benign(0.274) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| ATAD2B | SNV | Missense_Mutation | c.1040G>T | p.Arg347Ile | p.R347I | Q9ULI0 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-A7-A13F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| ATAD2B | SNV | Missense_Mutation | novel | c.4027N>G | p.Leu1343Val | p.L1343V | Q9ULI0 | protein_coding | tolerated(0.57) | benign(0.003) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATAD2B | SNV | Missense_Mutation | novel | c.4034N>A | p.Pro1345His | p.P1345H | Q9ULI0 | protein_coding | tolerated(0.69) | benign(0.012) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATAD2B | SNV | Missense_Mutation | c.1523N>G | p.Asp508Gly | p.D508G | Q9ULI0 | protein_coding | deleterious(0) | probably_damaging(0.93) | TCGA-AO-A12F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
| ATAD2B | SNV | Missense_Mutation | c.2740N>G | p.Gln914Glu | p.Q914E | Q9ULI0 | protein_coding | deleterious(0.03) | benign(0.012) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| ATAD2B | SNV | Missense_Mutation | c.3438A>T | p.Lys1146Asn | p.K1146N | Q9ULI0 | protein_coding | tolerated(0.47) | possibly_damaging(0.71) | TCGA-BH-A1F2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ATAD2B | SNV | Missense_Mutation | novel | c.1019N>T | p.Ser340Phe | p.S340F | Q9ULI0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A5J0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ATAD2B | SNV | Missense_Mutation | c.2018N>T | p.His673Leu | p.H673L | Q9ULI0 | protein_coding | deleterious(0.01) | possibly_damaging(0.543) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ATAD2B | SNV | Missense_Mutation | c.335N>T | p.Arg112Leu | p.R112L | Q9ULI0 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.915) | TCGA-E2-A15K-06 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 54454 | ATAD2B | ENZYME | inhibitor | 336446907 | ||
| 54454 | ATAD2B | ENZYME | inhibitor | 385612205 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |